2m 2m 2m 2m 2m 2m 2m
Tvardi Therap (TVRD)
NASDAQ
$2.95-$0.23 (-7.10%)
Price as of Jun 03, 2026 7:25 PM EDT- $31.7MMarket Cap
- -88.05%1-Year Change
- BiotechnologyIndustry
Tvardi Therap (TVRD)
$2.95-$0.23 (-7.10%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | 7.1M -65.96% | 21.0M -49.92% | 41.9M +81.81% | |
Cost of Revenue | N/A N/A | 620,000 -89.96% | 6.2M -15.03% | 7.3M N/A | |
Gross Profit | 0 -100.00% | 6.5M -55.95% | 14.8M -57.24% | 34.6M +50.26% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -18.0M -45.10% | -32.8M -69.77% | -108.5M +18.10% | -91.9M +11.10% | |
Depreciation and Amortization Expense | 95,000 -50.52% | 192,000 -25.87% | 259,000 +4.44% | 248,000 0.00% | |
Total Operating Expenses | 26.7M -59.18% | 65.5M -54.01% | 142.5M +10.09% | 129.4M +15.42% | |
Operating Profit | -26.7M -54.19% | -58.4M -51.95% | -121.5M +38.80% | -87.5M -1.74% | |
Interest Income | 700,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 700,000 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 7.2M +153.15% | 2.8M -21.14% | 3.6M +73.99% | 2.1M +221.03% | |
Income before Taxes | -26.7M -62.47% | -71.3M -41.34% | -121.5M +42.14% | -85.5M -3.35% | |
Income Taxes | 0 +100.00% | -398,000 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -18.2M -74.30% | -70.9M -40.20% | -118.5M +38.65% | -85.5M -3.35% | |
Net Income from Continuing Operations Applicable to Common | -18.2M -74.44% | -71.3M -39.87% | -118.5M +38.65% | -85.5M -3.35% | |
Basic EPS and Net Income | -2.46 -84.16% | -15.53 +609.13% | -2.19 +37.74% | -1.59 -8.62% | |
Diluted EPS and Net Income | -3.26 -79.01% | -15.53 +609.13% | -2.19 +37.74% | -1.59 -8.62% | |
Basic Weighted Average Shares | 7.4M +62.60% | 4.6M -91.57% | 54.1M +0.92% | 53.7M +5.79% | |
Diluted Weighted Average Shares | 7.8M +70.58% | 4.6M -91.57% | 54.1M +0.92% | 53.7M +5.79% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 20.7M -45.30% | 37.9M -26.79% | 51.8M -18.77% | 63.7M +373.81% | |
Short-Term Investments | 10.1M N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 30.8M -18.71% | 37.9M -26.79% | 51.8M -18.77% | 63.7M -61.84% | |
Total Current Assets | 31.5M -28.04% | 43.8M -62.27% | 116.2M -31.23% | 168.9M -2.53% | |
Accumulated Depreciation | N/A N/A | 1.7M 0.00% | 1.7M +18.31% | 1.4M +21.36% | |
Property and Plant and Equipment and Net | 52,000 -98.43% | 3.3M 0.00% | 3.3M +679.81% | 426,000 -32.49% | |
Total Long-Term Assets | 17,000 -99.49% | 3.3M 0.00% | 3.3M +679.81% | 426,000 -32.49% | |
Total Assets | 32.1M -26.82% | 43.8M -65.17% | 125.8M -30.94% | 182.2M -26.24% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 11.0M +178.00% | 4.0M -84.48% | 25.6M +9.10% | 23.5M +33.16% | |
Total Long-Term Debt | 30.3M N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 85,000 -98.60% | 6.1M 0.00% | 6.1M +217.41% | 1.9M 0.00% | |
Total Liabilities | 11.1M -77.02% | 48.4M -29.58% | 68.8M +170.96% | 25.4M +29.91% | |
Retained Earnings | -110.5M -85.38% | -755.6M +10.35% | -684.7M +20.93% | -566.2M +17.78% | |
Total Stockholders Equity | 20.9M +556.04% | -4.6M -108.05% | 57.1M -64.05% | 158.8M -30.21% | |
Total Shares Outstanding | 9.4M +105.23% | 4.6M -91.61% | 54.5M +1.27% | 53.8M +0.59% | |
Cash Flow | |||||
Cash from Operating Activities | -23.5M -61.42% | -60.9M -33.84% | -92.1M +16.95% | -78.7M +31.03% | |
Capital Expenditures | N/A N/A | 1.0M -55.96% | 2.4M +5,423.26% | 43,000 +10.26% | |
Cash from Investing Activities | -10.1M -120.69% | 48.7M +12.15% | 43.5M -66.23% | 128.7M +2,809.05% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 22.7M +729.94% | -3.6M -109.45% | 38.2M +12,167.20% | 311,000 -99.33% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | 91.31% +29.42% | 70.56% -14.63% | 82.65% -17.35% | |
Operating Margin | N/A N/A | -818.03% +41.18% | -579.43% +177.14% | -209.08% -45.95% | |
Return on Assets | -47.99% -42.55% | -83.53% +8.58% | -76.94% +93.21% | -39.82% +16.66% | |
Return on Equity | -222.76% -17.50% | -270.01% +145.90% | -109.80% +148.13% | -44.25% +19.22% | |
Revenue Growth | N/A N/A | -65.96% +32.14% | -49.92% -161.02% | 81.81% +198.62% | |
Current Ratio | 2.86 -74.11% | 11.03 +143.10% | 4.54 -36.97% | 7.20 -26.80% | |
Cash Ratio | 1.88 -80.32% | 9.54 +371.68% | 2.02 -25.54% | 2.72 +255.79% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow